Search

Genmab A-S

Închisă

2,177 1.63

Rezumat

Modificarea prețului

24h

Curent

Minim

2082

Maxim

2166

Indicatori cheie

By Trading Economics

Venit

243M

295M

Vânzări

259M

1.2B

P/E

Medie Sector

26.175

56.659

EPS

34.85

Marjă de profit

25.541

Angajați

3,119

EBITDA

216M

431M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.49% downside

Dividende

By Acuity

Următoarele câștiguri

5 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

19B

132B

Deschiderea anterioară

2175.37

Închiderea anterioară

2177

Genmab A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 sept. 2026, 23:56 UTC

Correlated Moves

Shares declined in after-market trading amid rising oil prices.

1 sept. 2026, 23:56 UTC

Cricut Inc shares are lower in after-market trading amid broader market pressures and declining oil prices, reflecting heightened inflation concerns.

1 sept. 2026, 23:56 UTC

Fidelity National Information Services remains near unchanged in after-market trading, with no specific news identified and a position below its 20-day moving average.

1 sept. 2026, 23:56 UTC

monday.com Ltd. shares traded roughly flat in after-market hours. The stock remains above its 20-day moving average and near the upper end of its one-month range.

1 sept. 2026, 23:56 UTC

Cognizant Technology Solutions shares are lower in after-market trading, amid broader market pressure from rising oil prices and geopolitical tensions.

1 sept. 2026, 23:56 UTC

News

Wix.com Ltd faces a securities class action lawsuit over alleged false statements about its AI products, leading shares to trade lower in after-market hours.

1 sept. 2026, 23:56 UTC

Becton Dickinson and Co shares rose in after-market trading, reflecting a position above its 20-day moving average and near the top of its one-month range.

1 sept. 2026, 23:56 UTC

United States Copper Index Fund is higher in after-market hours, maintaining resilience amid broader market declines driven by rising oil prices and inflation concerns.

1 sept. 2026, 23:56 UTC

Arbor Realty Trust Inc. shares rose in after-market trading, despite broader market pressures and rising oil prices raising inflation concerns among investors.

1 sept. 2026, 23:56 UTC

Travelers Companies Inc shares are lower in after-market hours, with no specific news identified. Rising oil prices contribute to broader inflation concerns affecting equities.

1 sept. 2026, 23:56 UTC

ON Semiconductor shares are lower in after-market hours, reflecting broader market pressure amid rising oil prices and inflation concerns.

1 sept. 2026, 23:56 UTC

Ecolab Inc shares are higher in after-market hours amid rising oil prices and geopolitical tensions, despite broader market pressures from inflation concerns.

1 sept. 2026, 23:56 UTC

Merit Medical Systems Inc shares are higher in after-market hours, reflecting strong performance despite broader market pressures from rising oil prices and inflation concerns.

1 sept. 2026, 23:56 UTC

Martin Marietta Materials Inc. shares are higher in after-market trading, recovering from earlier declines despite ongoing pressures from rising oil prices and inflation concerns.

1 sept. 2026, 23:56 UTC

News

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

1 sept. 2026, 23:56 UTC

Geron Corp shares are higher in after-market trading, reflecting a positive move since Tuesday's close amid broader market fluctuations. No specific news was identified.

1 sept. 2026, 23:56 UTC

Check Point Software Technologies shares are lower in after-market trading, following earlier volatility and broader market pressure from rising oil prices.

1 sept. 2026, 23:52 UTC

Clean Harbors Inc shares are lower in after-market trading, declining after a near-flat position. No specific news was identified to explain the movement.

1 sept. 2026, 23:52 UTC

Huntington Bancshares Inc shares are higher in after-market hours, recovering from a session low despite trading below its 20-day moving average.

1 sept. 2026, 23:51 UTC

Bank of Hawaii Corp shares are higher in after-market trading, recovering from an earlier dip. The stock remains below its 20-day moving average.

1 sept. 2026, 23:51 UTC

ETF Constituents
Macro News

iShares MSCI Germany ETF declines in after-market hours amid global equity market pressure from macroeconomic concerns and rising crude oil prices.

1 sept. 2026, 23:51 UTC

News

Telephone and Data Systems withdraws Array Digital Infrastructure acquisition proposal and resumes share repurchase program. Shares rise in after-market trading.

1 sept. 2026, 23:51 UTC

Correlated Moves

Shares of Comfort Systems USA Inc. declined in after-market trading, influenced by broader market sentiment and rising oil prices amid geopolitical tensions.

1 sept. 2026, 23:51 UTC

News
Correlated Moves

EOG Resources shares are higher after the company announced participation in the Barclays Energy-Power Conference, with oil prices surpassing $90 per barrel.

1 sept. 2026, 23:51 UTC

Unity Software Inc. shares are trading higher in after-market hours, breaking from a recent trend of consecutive daily gains.

1 sept. 2026, 23:51 UTC

Correlated Moves
Social Media

ConocoPhillips shares are lower in after-market hours amid broader energy sector scrutiny, despite rising crude oil prices above $90 per barrel.

1 sept. 2026, 23:51 UTC

Verizon Communications Inc shares are lower in after-market hours, with no specific news identified to explain the decline. Oil price increases raise inflation concerns.

1 sept. 2026, 23:51 UTC

European equities decline as oil prices surge and geopolitical tensions rise, fueling inflation fears and bond market sell-off ahead of potential ECB interest rate hikes.

1 sept. 2026, 23:51 UTC

Global equity markets decline as oil prices surge over 5% amid U.S.-Iran tensions, while weak U.S. job openings and Eurozone inflation rise raise concerns over economic stability.

1 sept. 2026, 23:51 UTC

U.S. equity indices decline as rising oil prices and bond yields heighten inflation fears amid geopolitical tensions, with investors bracing for potential stagflation risks.

Comparație

Modificare preț

Genmab A-S Așteptări

Obiectiv de preț

By TipRanks

-1.49% jos

Prognoză pe 12 luni

Medie 2,493.35 DKK  -1.49%

Maxim 3,320 DKK

Minim 308.417 DKK

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGenmab A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

3

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat